Microbial strain of lachnospiraceae, drug for preventing or treating tumors and use

Abstract

A microbial strain of Lachnospiraceae is a species of a genus of the family Lachnospiraceae (Lachnospiraceae sp.). The nucleotide sequence of 16S rRNA of the microbial strain of Lachnospiraceae is as shown in SEQ ID No. 1. The intestinal anaerobic microbial strain Lachnospiraceae sp. can inhibit the growth rate of tumors and can be used for preventing and/or treating tumors. The tumors include at least one of liver cancer, colon cancer, rectal cancer, colorectal cancer, lung cancer, breast cancer, cervical cancer, ovarian cancer, pancreatic cancer, cholangiocarcinoma, kidney cancer, and fibrosarcoma.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . An oral pharmaceutical composition comprising:
 a microbial strain of Lachnospiraceae; and   a pharmaceutically acceptable carrier in an enteric coating,   wherein the microbial strain of Lachnospiraceae is a species of a genus of the family Lachnospiraceae (Lachnospiraceae sp.), and the microbial strain of Lachnospiraceae has a 16S rRNA with the nucleotide sequence of SEQ ID No. 1, or with at least 95%, 96%, 97%, 97.5%, 98%, 98.65%, 98.7%, or 99% identity to the nucleotide sequence.   
     
     
         4 . The oral pharmaceutical composition according to  claim 3 , wherein the microbial strain of Lachnospiraceae comprises Lachnospiraceae MNH 46686 strain, which was deposited with the Guangdong Microbial Culture Collection Center with a deposit name of Lachnospiraceae sp. MNH 46686 and a deposit number of GDMCC No: 62002; or
 the microbial strain of Lachnospiraceae has an average nucleotide identity ANI value of at least 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%, to the Lachnospiraceae MNH 46686 strain.   
     
     
         5 - 9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . A method for inhibiting tumor growth, the method comprising:
 administering to a subject in need thereof the oral pharmaceutical composition of  claim 3     wherein the microbial strain of Lachnospiraceae is a species of a genus of the family Lachnospiraceae (Lachnospiraceae sp.), and the microbial strain of Lachnospiraceae has a 16S rRNA with the nucleotide sequence as shown in SEQ ID No. 1, or with at least 95%, 96%, 97%, 97.5%, 98%, 98.65%, 98.7%, or 99% identity to the nucleotide sequence.   
     
     
         12 . A method for treating or preventing a disease mediated by HDAC activity, the method comprising:
 administering to a subject in need thereof the oral pharmaceutical composition of  claim 3  comprising a microbial strain of Lachnospiraceae and a pharmaceutically acceptable carrier in an enteric coating, wherein the microbial strain of Lachnospiraceae is a species of a genus of the family Lachnospiraceae (Lachnospiraceae sp.), and the microbial strain of Lachnospiraceae has a 16S rRNA with the nucleotide sequence as shown in SEQ ID No. 1, or with at least 95%, 96%, 97%, 97.5%, 98%, 98.65%, 98.7%, or 99% identity to the nucleotide sequence.   
     
     
         13 . (canceled) 
     
     
         14 . A method for inhibiting tumor growth according to  claim 11 , wherein the microbial strain of Lachnospiraceae comprises Lachnospiraceae MNH 46686 strain, which was deposited with the Guangdong Microbial Culture Collection Center with a deposit name of Lachnospiraceae sp. MNH 46686 and a deposit number of GDMCC No: 62002;
 or the microbial strain of Lachnospiraceae has an average nucleotide identity ANI value of at least 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%, to the Lachnospiraceae MNH 46686 strain.   
     
     
         15 . A method for inhibiting tumor growth according to  claim 11 , wherein inhibiting tumor growth comprises at least one of: (a) inhibiting tumor volume growth; (b) inhibiting tumor weight increase; (c) inhibiting tumor cell growth; (d) improving the response rate to a tumor therapy; (e) improving the therapeutic efficacy of an immunosuppressive drug, such as improving the therapeutic efficacy of an Anti-PD-1 drug; (f) inhibiting tumor cell metastasis; (g) reducing Anti-PD-1 drug resistance; (h) increasing the proportion of NK cells in peripheral blood to activate the subject's systemic immunity; (i) inhibiting HDAC activity by at least one of acetic acid, propionic acid, butyric acid or valeric acid in SCFA; (j) inhibiting the tumor by at least one of acetic acid, propionic acid, butyric acid or valeric acid in SCFA; or (k) inhibiting the tumor by regulating the subject's immune system to exert an immunomodulatory effect. 
     
     
         16 . A method for inhibiting tumor growth according to  claim 11 , wherein the tumor comprises a solid tumor, soft tissue tumor, hematopoietic tumor, adenoma, or metastatic tumor. 
     
     
         17 . A method for inhibiting tumor growth according to  claim 11 , wherein the tumor is selected from at least one of liver cancer, colon cancer, rectal cancer, colorectal cancer, lung cancer, breast cancer, cervical cancer, ovarian cancer, pancreatic cancer, cholangiocarcinoma, kidney cancer, glioma, liposarcoma, melanoma, lymphoma, small cell lung cancer, squamous cell carcinoma, chondrosarcoma, or fibrosarcoma. 
     
     
         18 . A method for treating or preventing a disease mediated by HDAC activity according to  claim 12 , wherein the microbial strain of Lachnospiraceae comprises Lachnospiraceae MNH 46686 strain, which was deposited with the Guangdong Microbial Culture Collection Center with a deposit name of Lachnospiraceae sp. MNH 46686 and a deposit number of GDMCC No: 62002;
 or the microbial strain of Lachnospiraceae has an average nucleotide identity ANI value of at least 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%, to the Lachnospiraceae MNH 46686 strain.   
     
     
         19 . A method for treating or preventing a disease mediated by HDAC activity according to  claim 12 , wherein the disease mediated by HDAC activity comprises at least one of a tumor, metabolic disease, diabetes, autoimmune disease, infectious disease, central nervous disease, or inflammatory bowel disease. 
     
     
         20 . A method for treating or preventing a disease mediated by HDAC activity according to  claim 19 , wherein the tumor comprises a solid tumor, soft tissue tumor, hematopoietic tumor, adenoma or metastatic tumor. 
     
     
         21 . A method for treating or preventing a disease mediated by HDAC activity according to  claim 19 , wherein the tumor is selected from at least one of liver cancer, colon cancer, rectal cancer, colorectal cancer, lung cancer, breast cancer, cervical cancer, ovarian cancer, pancreatic cancer, cholangiocarcinoma, kidney cancer, glioma, liposarcoma, melanoma, lymphoma, small cell lung cancer, squamous cell carcinoma, chondrosarcoma or fibrosarcoma. 
     
     
         22 . A method for treating or preventing a disease mediated by HDAC activity according to  claim 19 , wherein the tumor is a tumor caused by viral infection or a tumor caused by bacterial infection, such as a tumor caused by infection with human papilloma virus, hepatitis B or C virus, human immunodeficiency virus, or Epstein-Barr virus, or a tumor caused by infection with  Helicobacter pylori  or  Fusobacterium nucleatum.